Chapter 3: Legal & Ethical Considerations in Pharmacology

Drug manufacturing, sales, safety, and efficacy are stringently regulated by federal legislation, primarily the Food and Drugs Act and the Controlled Drugs and Substances Act (CDSA), which utilizes various schedules to categorize substances based on their therapeutic use and potential for misuse. Health Canada’s Therapeutic Products Directorate (TPD) oversees compliance and the comprehensive drug approval process. This multi-year process requires extensive preclinical studies followed by four phases of human clinical trials (Phase I through Phase IV/postmarketing surveillance) to ensure safety, efficacy, and optimal dosage range, relying heavily on informed consent from participants and utilizing techniques like double-blind studies and placebos to mitigate bias. Nursing professionals must operate within the legal boundaries defined by provincial and territorial Nurse Practice Acts (NPAs) and adhere strictly to established standards of care to avoid liability for negligence or malpractice. Furthermore, patient privacy is safeguarded by federal acts like PIPEDA and various provincial laws that govern the secure handling of personal health information. Ethical nursing practice is fundamentally guided by core principles such as autonomy, beneficence, and justice, which are reinforced by codes of ethics from organizations like the Canadian Nurses Association (CNA) and the International Council of Nurses (ICN). While the nurse must act as a patient advocate, the use of inactive substances, or placebos, in general clinical practice—as opposed to sanctioned research—is generally viewed as an ethical dilemma due to the potential erosion of trust among the patient, nurse, and prescriber.